Cytosorbents Corporation
CTSO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.13 | -0.07 | -0.04 |
| FCF Yield | -29.70% | -45.58% | -51.36% | -10.07% |
| EV / EBITDA | -4.81 | -1.93 | -2.12 | -6.63 |
| Quality | ||||
| ROIC | -40.84% | -74.74% | -60.55% | -28.90% |
| Gross Margin | 70.59% | 70.62% | 59.77% | 72.46% |
| Cash Conversion Ratio | 0.70 | 0.76 | 0.86 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.86% | -8.14% | -4.20% | 20.78% |
| Free Cash Flow Growth | 34.88% | 34.88% | -89.70% | -150.87% |
| Safety | ||||
| Net Debt / EBITDA | -1.55 | -0.15 | 0.13 | 1.77 |
| Interest Coverage | -12.00 | -202.35 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.83 | 2.48 | 4.03 | 2.32 |
| Cash Conversion Cycle | 53.89 | 66.24 | 106.84 | 105.95 |